CureVac (NASDAQ:CVAC - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.27 per share and revenue of $20.58 million for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.
CureVac (NASDAQ:CVAC - Get Free Report) last issued its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The company had revenue of $15.44 million during the quarter, compared to analyst estimates of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
CureVac Stock Down 2.5 %
NASDAQ:CVAC traded down $0.08 during mid-day trading on Friday, reaching $3.12. The stock had a trading volume of 282,787 shares, compared to its average volume of 809,788. The stock's 50 day simple moving average is $3.08 and its two-hundred day simple moving average is $3.17. CureVac has a 1-year low of $2.22 and a 1-year high of $5.28. The company has a market capitalization of $699.93 million, a price-to-earnings ratio of 5.67 and a beta of 2.48. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reiterated a "market outperform" rating and issued a $16.00 price target on shares of CureVac in a report on Friday, February 14th.
Get Our Latest Research Report on CVAC
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Further Reading
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
